文献速递胸部肿瘤

奥希替尼一线治疗EGFR突变晚期NSCLC的成本效果分析

Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer.
PubMed 文献 · JAMA Oncol · 2018-01-01

该成本效果分析基于FLAURA试验个体数据及既往荟萃分析构建决策模型,评估奥希替尼对比一/二代EGFR-TKI一线治疗EGFR突变晚期NSCLC的10年成本效果。按WHO成本效果阈值,当前价格下奥希替尼在两国均不具成本效果。

要点

  • 奥希替尼对比一/二代EGFR-TKI的增量QALY为0.594。
  • 奥希替尼降价可改善成本效果,10%折扣使ICER降20%。

核心结论

  • 按WHO成本效果阈值,当前价格下奥希替尼一线治疗EGFR突变晚期NSCLC在美国和巴西均不具成本效果。

研究设计与样本

  • 基于FLAURA随机临床试验个体患者数据及既往荟萃分析构建决策分析模型。
  • 比较奥希替尼与一/二代EGFR-TKI,时间跨度10年,采用美国与巴西支付方视角。

主要发现

  • 奥希替尼对比一/二代EGFR-TKI的增量QALY为0.594。
  • 美国ICER:对比厄洛替尼226 527美元,对比吉非替尼231 123美元,对比阿法替尼219 874美元。
  • 巴西ICER:对比厄洛替尼162 329美元,对比吉非替尼180 804美元,对比阿法替尼175 432美元。
  • FLAURA总生存HR 0.63(95%CI 0.45-0.88)与ICER关联最强,ICER范围84 342至859 771美元。
  • 奥希替尼采购成本降低10%使ICER较基线下降20%,降低20%使ICER下降40%。

临床怎么用

  • 在当前美国与巴西价格下,奥希替尼一线治疗不符合WHO成本效果阈值。
  • 药品降价可显著改善奥希替尼的成本效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The survival of patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) gene mutations has improved substantially in the last decade with the development of targeted tyrosine kinase inhibitors (TKIs). Osimertinib, a third-generation TKI that is approved by the US Food and Drug Administration for the treatment of patients who develop EGFR T790M mutations, has recently shown improved clinical outcomes compared with gefitinib and erlotinib for treatment-naive patients. OBJECTIVE: The aim of this study was to assess the cost-effectiveness of osimertinib for the first-line treatment of patients with EGFR-mutated NSCLC. DESIGN, SETTING, AND PARTICIPANTS: For this cost-effectiveness analysis, we extracted individual patient data from the FLAURA randomized clinical trial and used findings of our earlier meta-analysis to develop a decision-analytic model and determine the cost-effectiveness of osimertinib (AZD9291) compared with first- and second-generation EGFR-TKIs over a 10-year time horizon. All direct costs were based on US and Brazilian payer perspectives. MAIN OUTCOMES AND MEASURES: The main outcome of this study was the incremental cost-effectiveness ratio (ICER) expressed as cost per quality-adjusted life-year (QALY) gained by using osimertinib compared with first- or second-generation EGFR-TKIs in previously untreated EGFR-mutated NSCLC. RESULTS: In the base case using the data as reported in the FLAURA trial, the incremental QALY for osimertinib was 0.594 compared with the first- and second-generation EGFR-TKIs. In the United States, the osimertinib ICERs were $226 527 vs erlotinib, $231 123 vs gefitinib, and $219 874 vs afatinib. In Brazil, the ICERs were $162 329, $180 804, and $175 432, respectively. The overall survival (95% CI) reported in the FLAURA trial (hazard ratio, 0.63; 95% CI, 0.45-0.88) had the strongest association with the ICER (ranging from $84 342 to $859 771). Osimertinib price adjustments to the FLAURA trial data improved cost-effectiveness. For example, a discount of 10% on osimertinib acquisition cost was associated with a 20% decreased ICER compared with the base case ICER, and a discount of 20% on osimertinib acquisition cost was associated with a 40% decreased ICER compared with the base case ICER. CONCLUSIONS AND RELEVANCE: At current costs, by World Health Organization cost-effectiveness threshold criteria, osimertinib is not cost-effective for first-line therapy of EGFR-mutated NSCLC in either the United States or Brazil.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Aguiar PN, Haaland B, Park W, et al. Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2018. PMID: 29852038. doi:10.1001/jamaoncol.2018.1395

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。